US biotechs feel the pressure on data exclusivity
This article was originally published in Scrip
Should biotech firms abandon hope of securing a 12-14-year data exclusivity period in the forthcoming US biosimilars legislation? Certainly things don't seem to be going their way after President Barack Obama came out in favour of a compromise seven-year term, citing the recent Federal Trade Commission report that dismissed the need for anything like 14 years of protection.
You may also be interested in...
The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."
A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesevir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.